Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~22 mi. (Kryvyy Rih, Ukraine, +207 more cities)

MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2700)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

~22 mi. (Kryvyy Rih, Ukraine, +190 more cities)

MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department

ATM Loss, +27 more biomarkers

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

~22 mi. (Kryvyy Rih, Ukraine, +45 more cities)

MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council ( Site 1804)

Esophageal Squamous Cell Carcinoma

cisplatin, +5 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

~98 mi. (Kropyvnytskyy, Ukraine, +158 more cities)

LLC Ukrainian Center of Tomotherapy ( Site 2105)

Non-Small Cell Lung Carcinoma

olaparib, +4 more drugs

chemotherapy, +3 more types

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~98 mi. (Kropyvnytskyy, Ukraine, +150 more cities)

Ukrainian Center of Tomotherapy ( Site 1708)

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~98 mi. (Kropyvnytskyy, Ukraine, +137 more cities)

Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 1451)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

~98 mi. (Kropyvnytskyy, Ukraine, +92 more cities)

Ukranian Center of TomoTherapy ( Site 0140)

Bladder Urothelial Carcinoma

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

~98 mi. (Kropyvnytskyy, Ukraine, +67 more cities)

Ukrainian Center of Tomotherapy ( Site 1807)

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

carboplatin, +5 more drugs

chemotherapy, +1 more type

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

~98 mi. (Kropyvnytskyy, Ukraine, +145 more cities)

Ukrainian Center of Tomotherapy ( Site 2206)

Non-Small Cell Lung Carcinoma

pembrolizumab, +1 more drug

immunotherapy, +2 more types

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

~98 mi. (Kropyvnytskyy, Ukraine, +115 more cities)

Kirovograd Regional oncology Dispensary ( Site 1716)

ATM Loss, +27 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib, +1 more drug

immunotherapy, +1 more type

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~99 mi. (Antonivka, Ukraine, +163 more cities)

Communal nonprofit enterprise "Kherson Regional Oncology Dispensary" of Kherson Regional Council (

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types